Zydus and Synthon inks licensing and supply agreement for Palbociclib Tablets for US market

Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets

Glenmark Life Sciences inks CDMO supply deal with a Japanese pharma innovator

Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator

Venus Remedies eceives GMP certification from Libya

The certification underscores Venus Remedies Limited's adherence to stringent quality control measures

Pharmatech Associates adds Dr. Praveen Tyle to Board of Trustees

Parexel collaborates with Japanese Foundation for cancer research

Collaboration streamlines patient access to oncology clinical trials

BioAsia 2024 to focus on data and AI for life sciences

The three-day forum will feature global leaders, scientists, regulatory body representatives, industry associations, and academia among many others

USFDA accepts sBLA of TIVDAK for priority review for patients with metastatic cervical cancer

Submission based on positive results from global phase 3 study demonstrating overall survival benefit of TIVDAK over chemotherapy

GSK to acquire Aiolos Bio for US$ 1 billion upfront payment

Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway

Caplin Group announces strategic investment of Rs. 700 crore in TN

This investment will be made by Caplin Point Laboratories Limited and its subsidiaries - Caplin Steriles Limited and Caplin One Labs Limited

European Commission approves Pfizer’s Talzenna in combination with Xtandi for treatment of metastatic castration-resistant prostate cancer

TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union